9
Participants
Start Date
February 29, 2008
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
Terbutaline
"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
Nemours Children's Clinic, Jacksonville
Jaeb Center for Health Research, Tampa
Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City
Washington University, St Louis
Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford
Department of Pediatrics, Yale University School of Medicine, New Haven
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Jaeb Center for Health Research
OTHER